The latest update is out from Forte Biosciences (FBRX).
Forte Biosciences, Inc. successfully conducted its 2024 annual stockholders meeting, resulting in the election of Class I directors and the ratification of KPMG LLP as the independent accounting firm for the upcoming fiscal year. Additionally, stockholders approved an amended Equity Incentive Plan and a reverse stock split of not less than 1-for-5 and not more than 1-for-30. The board finalized the reverse stock split at a 1-for-25 ratio, to be effective from August 28, 2024, with proportional adjustments to outstanding equity awards and future issuance plans. No fractional shares will be issued, with stockholders receiving cash compensation instead.
For a thorough assessment of FBRX stock, go to TipRanks’ Stock Analysis page.
